| Reference | </br>1:Application of 19F-n.m.r. spectroscopy to the identification of dog urinary metabolites of imirestat, a spirohydantoin aldose reductase inhibitor. Gilbert PJ, Hartley TE, Troke JA, Turcan RG, Vose CW, Watson KV.Xenobiotica. 1992 Jul;22(7):775-87. PMID: 1455900 </br>2:Saturable tissue binding and imirestat pharmacokinetics in rats. Chien JY, Banfield CR, Brazzell RK, Mayer PR, Slattery JT.Pharm Res. 1992 Apr;9(4):469-73. PMID: 1495891 </br>3:Aldose reductase inhibition with imirestat-effects on impulse conduction and insulin-stimulation of Na+/K(+)-adenosine triphosphatase activity in sciatic nerves of streptozotocin-diabetic rats. Carrington AL, Ettlinger CB, Calcutt NA, Tomlinson DR.Diabetologia. 1991 Jun;34(6):397-401. PMID: 1653157 </br>4:Capillary gas chromatographic-electron-capture assay for the aldose reductase inhibitor imirestat in lens and plasma. McCue BA, Park YH, Brazzell RK, Boltralik JJ.J Chromatogr. 1991 Apr 19;565(1-2):255-64. PMID: 1908477 </br>5:Dose-dependent pharmacokinetics of the aldose reductase inhibitor imirestat in man. Brazzell RK, Mayer PR, Dobbs R, McNamara PJ, Teng RL, Slattery JT.Pharm Res. 1991 Jan;8(1):112-8. PMID: 1901647 </br>6:Scintigraphic evaluation of the ocular disposition of 18F-imirestat in rabbits. Vaidyanathan G, Jay M, Bera RK, Mayer PR, Brazzell RK.Pharm Res. 1990 Nov;7(11):1198-200. No abstract available. PMID: 2127314 </br>7:Pharmacokinetics of the aldose reductase inhibitor imirestat following topical ocular administration. Brazzell RK, Wooldridge CB, Hackett RB, McCue BA.Pharm Res. 1990 Feb;7(2):192-8. PMID: 2106677 </br>8:Effect of protein binding on the high-performance liquid chromatography of phenytoin and imirestat in human serum by direct injection onto internal surface reversed-phase columns. Pinkerton TC, Miller TD, Janis LJ.Anal Chem. 1989 May 15;61(10):1171-4. No abstract available. PMID: 2751110
|
